Latest News

ANZ Group Holdings (ASX:ANZ) has come into focus after its shares fell nearly 2% during a broader selloff in Australian banks, ahead of key Australia CPI data and the next Reserve Bank of Australia meeting. See our latest analysis for ANZ Group Holdings. That sector wide drop sits against a mixed backdrop for ANZ Group Holdings, with the share price at A$35.68, a 90 day share price return of 2.35% and a 1 year total shareholder return of 27.77%. This suggests longer term momentum has held up...

CVS Health (CVS) is back in focus after affirming a quarterly dividend of $0.665 per share and highlighting an AI-led digital push, including a new engagement platform and an expanded retail media network. See our latest analysis for CVS Health. CVS Health shares trade at US$80.60, with recent news around its affirmed dividend, AI native engagement platform and expanded PBM contracts coming alongside a 3.5% 90 day share price return and an 82.7% 1 year total shareholder return. This suggests...

If you are wondering whether Northwest Bancshares at around US$12.40 offers fair value or a potential gap between price and worth, this breakdown is designed for you. The stock has delivered returns of 3.3% over the last week, 0.7% over the past month, 3.5% year to date, 2.6% over one year and 21.4% over five years, which gives useful context before comparing the current price to fundamentals. Recent attention on Northwest Bancshares has focused on its position within the U.S. regional...

Why Avis Budget Group (CAR) is on investors’ radar today Avis Budget Group (CAR) is drawing attention after recent trading, with the stock last closing at $127.57 and showing a mixed pattern across recent timeframes, including a negative past 3 months but a positive 1 year total return. See our latest analysis for Avis Budget Group. The recent 1 month share price return of a 4.75% decline and 3 month share price return of a 13.21% decline contrast with a 1 year total shareholder return of...

HEICO recently reported a series of record quarterly results across fiscal 2024 and 2025, with both its Flight Support Group and Electronic Technologies Group benefiting from strong organic demand and contributions from multiple acquisitions across aerospace, defense, and specialty electronics. These results underline how HEICO’s disciplined acquisition program and growing exposure to areas such as missile defense and avionics repair are reshaping its business mix and earnings profile. We’ll...

If you are wondering whether Dutch Bros at around US$63 per share is priced for perfection or still offers value, this article walks through the key numbers that matter. The stock has recent returns of 3.0% over 7 days, 7.1% over 30 days, 1.4% year to date and 12.2% over 1 year. These figures may catch the eye of investors thinking about growth potential and changes in risk appetite. Recent news coverage has focused on Dutch Bros as a growing US coffee chain, highlighting its store footprint...

If you are wondering whether Crocs at around US$86.57 is a bargain or just fairly priced, you are not alone. This article is designed to help you make sense of that question. The stock has seen mixed returns, with gains of 1.2% over the last 7 days and 1.0% over the last 30 days, set against a 0.4% year to date dip and a 21.1% decline over the past year. The 3 year return stands at a 31.9% decline and the 5 year return at 13.9%. Recent discussion around Crocs has focused on how the brand is...

Fanuc (TSE:6954) has drawn fresh attention as investors reassess its performance in industrial automation, with recent share moves and fundamental data prompting closer scrutiny of growth, profitability and valuation trade offs. See our latest analysis for Fanuc. At a share price of ¥6,296, Fanuc’s recent 1 day share price decline of 2.07% contrasts with a 90 day share price return of 31.72% and a 1 year total shareholder return of 55.40%. This suggests earlier momentum has been strong even...

Key Insights Significant control over RFHIC by individual investors implies that the general public has more power to...

In early January 2026, Wabtec Corporation announced a US$386 million follow-on order to supply additional R255 hybrid battery-diesel work locomotives and spare parts to New York’s Metropolitan Transportation Authority, with production in Erie, Pennsylvania and deliveries beginning in 2027. This deal highlights growing rail operator interest in lower-emission, digitally enabled maintenance locomotives that can operate in battery-only mode for tunnel work and support data-driven upkeep across...

Trimble announced in early January 2026 that its RTX and ProPoint Go positioning technologies will power Lucid Gravity’s navigation and driver-assistance systems, enabling centimeter-level accuracy even in tunnels, parking garages and dense urban areas where standard GPS often underperforms. This integration highlights how Trimble’s high-precision, software-driven positioning engine can quietly underpin advanced EV features from hands-free driving assist to fleet intelligence and enhanced...

Abivax has outlined its 2026 corporate outlook, emphasizing obefazimod’s potential in ulcerative colitis after the December 2025 ABTECT Phase 3 DSMB meeting reported no new safety signals and over 80% patient completion of the 44‑week maintenance trial. An interesting takeaway is the company’s plan to leverage these Phase 3 data to pursue a US regulatory filing for obefazimod later in 2026, underscoring its ambitions in the ulcerative colitis treatment market. Next, we’ll examine how the...

If you are wondering whether Bloom Energy's share price still makes sense after a strong run, this article walks through how the current price stacks up against several valuation checks. The stock closed at US$121.84, with returns of 40.2% over the last 7 days, 11.3% over 30 days, 23.5% year to date, about 400% over 1 year, and just over 4x over 3 years, which has naturally sharpened questions about future risk and reward. Recent attention on Bloom Energy has been shaped by ongoing interest...

Clear Secure (YOU) drew fresh attention after its shares rose 4.7% following investor enthusiasm at the CES 2026 conference, where artificial intelligence and data analytics were key themes for technology companies. See our latest analysis for Clear Secure. That CES-related jump comes on top of a 23.03% 90-day share price return and a 5.96% year to date share price return. The 1-year total shareholder return of 37.84% and 3-year total shareholder return of 36.86% indicate momentum has...

Forestar Group (FOR) recently reported continued momentum in lot sales and profitability, with resilient margins and strong homebuilder demand, a combination that has helped underpin recent share gains and institutional confidence. See our latest analysis for Forestar Group. Forestar’s recent update on lot sales and profitability comes as the share price sits at $25.61, with a 5.3% year to date share price return and a three year total shareholder return of 50.21%, suggesting momentum has...

Most readers would already be aware that Shriram Pistons & Rings' (NSE:SHRIPISTON) stock increased significantly by 23...

If you are wondering whether MPLX is still good value at around US$52.55, you are not alone. The answer depends on how you look at the stock. The recent share price sits about 1.5% lower over the past week and 4.8% lower over the past month, even though the 1 year return is 17.2% and the 3 year return is 98.2%, with a very large 5 year gain of 233.8%. Recent coverage has focused on MPLX as a midstream energy business with income oriented appeal and ongoing investor interest in its...

In recent days, Advanced Drainage Systems reported fiscal second-quarter 2026 results that surpassed analyst expectations for both earnings per share and revenue, prompting a wave of optimistic commentary from research firms. This outperformance reinforces the company’s focus on higher-value water management solutions and operational efficiency, which have become central themes in how analysts view its longer-term potential. With quarterly results beating forecasts and reinforcing product...

If you are wondering whether Rigetti Computing's share price still reflects its true worth, you are not alone. This article focuses squarely on what you might be paying for each dollar of potential. The stock closed at US$25.25 recently, with returns of 14% over the past 7 days, a 10.5% decline over 30 days, 7% year to date and 151.5% over the last year, plus a very large 3 year return that signals shifting expectations around risk and opportunity. Recent attention around Rigetti has...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Kinaxis (TSX:KXS) has appointed Razat Gaurav as CEO, effective January 12, 2026, along with a concurrent board seat, placing a seasoned supply chain and AI-focused leader at the center of the investment story. See our latest analysis for Kinaxis. The CEO announcement comes as Kinaxis shares trade at CA$175.48, with a 3.13% 1-day share price return and a modest 2.63% 1-year total shareholder return. This suggests shorter term momentum is picking up while longer term gains have been more...

If you are wondering whether Fortinet shares are priced attractively today, it helps to step back and separate short term noise from what the business might be worth over time. The stock closed at US$78.05 most recently, with a 1.7% decline over the last 7 days, a 6.5% decline over 30 days, a roughly flat 0.2% return year to date, and longer term returns of an 18.7% decline over 1 year, 61.3% over 3 years and 164.5% over 5 years. Recent price moves have played out against a backdrop of...

argenx (ENXTBR:ARGX) is back in focus after a leadership reshuffle, with Chief Operating Officer Karen Massey set to become CEO and Executive Director as co founder Tim Van Hauwermeiren moves to non executive chairman. See our latest analysis for argenx. The leadership announcement came after a period of mixed momentum, with a 30 day share price return of a 9.29% decline but a 1 year total shareholder return of 8.5%, and longer term total shareholder returns over 3 and 5 years remaining...

In recent days, PROCEPT BioRobotics has attracted heightened attention as multiple Wall Street firms updated their views on the company, with new coverage, ratings changes, and fresh commentary on its robotic treatments for benign prostatic hyperplasia. The mix of supportive and more cautious analyst opinions reinforces how central PROCEPT’s Aquablation technology and utilization trends are to investor expectations around its future role in urologic care. We’ll now examine how this new wave...